Biogen Idec Inc (BIIB) 385.05 $BIIB
Stocks Extend Losses; Amazon, Visa Headline After-Hours Action
at Investor's Business Daily - 1 hr 36 mins ago
Sellers were in the stock market again Thursday as Wall Street digested another avalanche of second-quarter earnings reports. At the close, the Dow Jones industrial average had lost 0.7%, the S&P 500 fell 0.6% and the Nasdaq had shed 0.5%....
BIIB: 385.05 (-6.69), UA: 95.93 (+6.56), AMZN: 482.18 (-6.09), VRX: 253.84 (+14.92), SAVE: 61.37 (+1.32), V: 71.75 (-0.22), CYBR: 61.72 (+4.22), ABBV: 70.52 (-0.04), FTNT: 46.83 (+4.53)
Eli Lilly, Biogen Present Data at Alzheimer's Association - Analyst Blog
Zacks Equity Research - Zacks Investment Research - 2 hrs 47 mins ago
Eli Lilly (LLY) and Biogen presented data on their Alzheimer's disease candidates, solanezumab and aducanumab, respectively at the Alzheimer's Association.
BIIB: 385.05 (-6.69), AGIO: 118.42 (+1.04), AMAG: 71.31 (-1.23), LLY: 86.76 (+0.38)
Should You Buy Biogen (BIIB) Ahead of Earnings? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jul 23, 7:40AM CDT
Analysts have very recently bumped up their estimates for Biogen, suggesting that a beat might be in the cards for the upcoming report
BIIB: 385.05 (-6.69)
Downgrade Alert for Biogen Idec (BIIB)
Comtex SmarTrend(R) - Thu Jul 23, 7:14AM CDT
Biogen Idec (NASDAQ:BIIB) was downgraded from Overweight to Neutral at Piper Jaffray today. The stock closed yesterday at $391.74 on volume of 4.0 million shares, above average daily volume of 1.4 million. Biogen Idec share prices have moved between a 52-week high of $480.18 and a 52-week low of $290.85 and closed yesterday at 35% above that low price at $391.74 per share. The 200-day and 50-day moving averages have moved 0.32% higher and 0.16% higher over the past week, respectively.
BIIB: 385.05 (-6.69)
Will Biogen Earnings Be a Biotech Bloodbath?
at The Street - Thu Jul 23, 6:43AM CDT
Biogen is one of the greatest biotech companies on the planet, and it reports earnings on Friday morning. It could disappoint investors again.
BIIB: 385.05 (-6.69)
Illumina Breaches Key Level On Q2 Sales Miss
at Investor's Business Daily - Wed Jul 22, 3:54PM CDT
Illumina (ILMN) surpassed second quarter earnings estimates late Tuesday but missed on revenue for the first time in six years. Analysts expected a beat-and-raise from the maker of gene sequencing systems, so its shares suffered in the stock market...
BIIB: 385.05 (-6.69), VRX: 253.84 (+14.92), DGX: 74.40 (+1.93), ILMN: 219.94 (+2.45), ABBV: 70.52 (-0.04), CELG: 139.01 (+0.75)
Isis Pharmaceuticals Begins Huntington's Disease Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 22, 2:20PM CDT
Isis Pharmaceuticals' (ISIS) Huntington's disease candidate, ISIS-HTTRx, moves into a phase I/IIa study; earns a milestone payment of $22 million from Roche.
BIIB: 385.05 (-6.69), ISIS: 55.08 (-0.30), AMAG: 71.31 (-1.23)
5 Stocks to Watch for Thursday and Friday.
ESTMZ - Wed Jul 22, 10:51AM CDT
Reports for Thursday, July 23 Report for Friday, July 24 Under Armour (UA) Under Armour (UA) will report its FQ2 ’15 results before the opening bell on Thursday. For Under Armour, while sales are expecting to continue their streak of...
SBUX: 56.56 (-0.13), AMZN: 482.18 (-6.09), BIIB: 385.05 (-6.69), UA: 95.93 (+6.56), DNKN: 53.75 (-2.78), SPY: 210.18 (-1.19), CMG: 725.94 (+0.12), MCD: 97.09 (-0.49), KKD: 18.22 (-0.29), YUM: 87.82 (-1.49)
US Blood Cancer Drug Market & Pipeline Analysis 2015
M2 - Wed Jul 22, 10:15AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hp4cd3/us_blood_cancer) has announced the addition of the "US Blood Cancer Drug Market & Pipeline Analysis 2015" report to their offering. Chemotherapeutic drugs are widely used therapeutics for the treatment of blood cancer in US. The future would witness a novel chemotherapeutics which are currently under various stages of research and development. Liposomal, pegylated and other improved versions are being made to offer higher therapeutic benefit along with minimized side effects. This will also help in increasing the number of indications and market volume by introduction of new chemotherapeutic products. They would have higher safety and efficacy levels as compared to their traditional counterparts. It will help in occupying large market shares and compete effectively with presently available drugs. Monoclonal antibodies are known for their superior pharmacological profiles and fewer side effects due to which they are widely accepted. Few monoclonal antibodies have been already introduced in US market. They have been able to generate significant revenues which are encouraging pharmaceutical companies to venture in this segment. Tyrosine kinase inhibitors are another major component of this market which has received lots of commercial success owing to their superior pharmacological efficacy. Both of them are far superior then chemotherapeutics and it is expected that blood cancer drugs belonging to different drug categories would be introduced in US market. Innovative blood cancer therapeutics is likely to generate huge revenues for the pharmaceutical companies in the next few years. However, few hurdles have to be passed like heterogeneous nature of blood cancer; it consists of different cells with different functions and it becomes difficult to eliminate them with single type of therapeutic. In this regard, only single therapeutic for different blood cancers have been introduced in US market till date. This strategy is likely to be followed by other pharmaceutical companies due to which competition in multiple blood cancer segments will increase. Market introduction of such therapeutics is likely to be widely accepted leading to generation of significant revenues. More blood cancer therapeutics is likely to enter in US market due to which its size will increase. "US Blood Cancer Drug Market & Pipeline Analysis 2015" Report Highlights: - Blood Cancer Incidence & Prevalence - Blood Cancer Drug Market Overview - Blood Cancer Drug Market Dynamics - Leukemia, Lymphoma & Myeloma Drug Clinical Pipeline Insight - Leukemia, Lymphoma & Myeloma Drug Clinical Pipeline: 435 Drugs - Majority Drugs in Phase-I Clinical Trials: 128 Drugs - Marketed Leukemia, Lymphoma & Myeloma Drug Clinical & Patent Analysis - Marketed Leukemia, Lymphoma & Myeloma Drug: 48 Drugs Key Topics Covered: 1. US Blood Cancer Incidence & Prevalence 2. US Blood Cancer Drug Market Overview 3. US Blood Cancer Drug Market Dynamics 4. US Blood Cancer Drug Market Future Prospects 5. Mechanism of Blood Cancer Therapeutics 6. Leukemia Drug Clinical Pipeline by Company & Phase 7. Marketed Leukemia Drug Clinical Insight 8. Lymphoma Drug Clinical Pipeline by Company & Phase 9. Marketed Lymphoma Drug Clinical Insight 10. Multiple Myeloma Drug Clinical Pipeline by Company & Phase 11. Marketed Multiple Myeloma Drug Clinical Insight 12. Multiple Blood Cancer Drug Clinical Pipeline by Company & Phase 13. Marketed Multiple Blood Cancer Drug Clinical Insight 14. Competitive Landscape - ARIAD Pharmaceuticals - Actelion Pharmaceuticals - Amgen - Astellas Pharma - Baxter BioScience - Bayer HealthCare Pharmaceuticals Inc. - Biogen Idec - Bristol-Myers Squibb - CASI Pharmaceuticals - Celera Genomics Group - Celgene Corporation - Eisai Co Ltd - Genmab - Gilead Sciences - GlaxoSmithKline - Hospira - Johnson & Johnson - Millennium Pharmaceuticals - Nova Laboratories - Novartis - Onxeo SA - Onyx Pharmaceuticals - Otsuka Pharmaceutical - Pfizer - Roche - SRI International - Scripps Clinic - Seattle Genetics - Southern Research Institute - Tekmira Pharmaceuticals Corporation - Teva Pharmaceutical Industries - Yakult Honsha For more information visit http://www.researchandmarkets.com/research/hp...ood_cancer
BIIB: 385.05 (-6.69), TKMR: 10.73 (+0.39), AMGN: 164.10 (-0.15), GSK: 42.00 (-0.30), BMY: 68.24 (-1.13), CASI: 1.64 (-0.07), JNJ: 100.20 (+0.02), GILD: 117.66 (+0.22), TEVA: 62.51 (unch), ARIA: 8.05 (-0.18), NVS: 103.05 (+1.75), CELGZ: 2.20 (-0.09)
Biotech Stock Roundup: Amgen PCSK9 Inhibitor First to Gain Approval, Exelixis Up on Positive Data - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Jul 22, 9:52AM CDT
Amgen's (AMGN) potential blockbuster, Repatha, is the first PCSK9 inhibitor to gain approval in the world for the treatment of high cholesterol.
BIIB: 385.05 (-6.69), ALXN: 207.84 (+1.68), AMGN: 164.10 (-0.15), ABBV: 70.52 (-0.04), REGN: 556.61 (+0.08), FPRX: 24.47 (-0.58), EXEL: 5.88 (-0.43)
Eli Lilly's Solanezumab Is the Alzheimer's Drug Equivalent of the Internet Dress
at The Street - Wed Jul 22, 6:00AM CDT
Lilly uses a new but contentious methodology to suggest treatment benefit from its experimental Alzheimer's drug.
BIIB: 385.05 (-6.69), LLY: 86.76 (+0.38)
Biogen Presents New Data from Phase 1B Study of Investigational Alzheimer's Disease Treatment Aducanumab (BIIB037) at Alzheimer's Association International Conference(R) 2015
Business Wire - Wed Jul 22, 5:45AM CDT
Today Biogen (NASDAQ: BIIB) announced new results from a prespecified interim analysis of PRIME, the Phase 1b placebo-controlled study of aducanumab (BIIB037) in patients with prodromal or mild Alzheimer's disease (AD). In this analysis, which includes patients treated up to 54 weeks with the 6 mg/kg dose, aducanumab demonstrated acceptable safety and tolerability, and the findings reinforce the previously reported results from PRIME. These data are being presented today at the Alzheimer's Association International Conference(R) 2015 (AAIC(R)) in Washington, D.C.
BIIB: 385.05 (-6.69)
Big Week for Biogen
Brian Orelli, The Motley Fool - Motley Fool - Tue Jul 21, 4:48PM CDT
Biogen 's investors are in store for a double dose of news this week. On Wednesday, the biotech is scheduled to present data for its Alzheimer's disease drug, aducanumab, and then on Friday we'll get second-quarter earnings from Biogen. Which will...
BIIB: 385.05 (-6.69)
Celgene Buys Receptos. Is Arena Pharmaceuticals Next?
Brian Orelli, The Motley Fool - Motley Fool - Tue Jul 21, 3:27PM CDT
Arena Pharmaceuticals (NASDAQ: ARNA) jumped more than 6% last Wednesday. But it had nothing to do with the biotech's only approved drug, obesity treatment Belviq. It wasn't even anything Arena Pharmaceuticals did. Instead, it appears the bump...
BIIB: 385.05 (-6.69), RCPT: 228.27 (-0.13), ARNA: 4.15 (-0.10), NVS: 103.05 (+1.75), CELG: 139.01 (+0.75)
Will AmerisourceBergen (ABC) Disappoint Earnings in Q3? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jul 21, 11:50AM CDT
AmerisourceBergen carries a Zacks Rank #4 (Sell) with an Earnings ESP of 0.00% and is scheduled to report third-quarter fiscal 2015 results on Jul 23, 2015.
BIIB: 385.05 (-6.69), ABC: 110.12 (-4.83), WBA: 95.48 (-1.16), MDCO: 34.00 (+0.16)
Why This Analyst Expects New Alzhemier’s Trials Could Produce the Most Important Drugs in History
ESTMZ - Tue Jul 21, 11:24AM CDT
Welcome to the July 21st edition of This Week on Estimize. We are pleased to be joined by Joe McCann, former biotech analyst and founder of Slingshot Insights, a company that works to provide professional caliber investment tools to sophisticated...
BIIB: 385.05 (-6.69), SPY: 210.18 (-1.19), GILD: 117.66 (+0.22), ZGNX: 20.27 (-0.71), UTHR: 175.10 (+0.50), RTRX: 34.18 (-0.75), LLY: 86.76 (+0.38), CELG: 139.01 (+0.75), XOMA: 1.04 (+0.04)
Global Inflammatory Bowel Disease Market 2015-2019 - Dominance of Market by Biologics
M2 - Tue Jul 21, 10:17AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vhn6mx/global) has announced the addition of the "Global Inflammatory Bowel Disease Market 2015-2019" report to their offering. This report covers the present scenario and the growth prospects of the Global Inflammatory Bowel Disease market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various drugs used in the treatment of inflammatory bowel disease. The market includes data from the sales of various drusg which are used for the treatment of Crohn's Disease and Ulcerative Colitis. The dominance of the market by biologics used to treat patients suffering from the disease is one of the emerging trends. Biologics are expected to become a preferred treatment option for the medical fraternity, patients, and the families of patients during the forecast period. This leads to a rise in the number of treatment-seeking patients, which increases the overall consumption of medicines. According to the report, the high prevalence of inflammatory bowel disease among the population resulting in a rise in the number of treatment-seeking patients has led to increased consumption of medications, thereby having a positive impact on the market share of the vendors. Further, the report states the high cost of drugs used to treat patients suffering from inflammatory bowel disease is one of the major challenges hindering the growth of the market. On the basis of the functioning of the drugs used for treatment, the Global Inflammatory Bowel Disease market is categorized into three segments. - 5-ASA - Antibiotics - Immunomodulators On the basis of the type of molecule used for treatment, the Global Inflammatory Bowel Disease market is categorized into two segments. - Biologics - Small Molecules On the basis of route of administration adopted for the treatment, the Global Inflammatory Bowel Disease market is categorized into two segments. - Oral - Parenteral On the basis of the form of drug used to treat the disease, the Global Inflammatory Bowel Disease market is categorized into two segments. - Solid - Liquid Key Vendors - Abbvie - Biogen Idec - Janssen Pharmaceuticals - Merck & Company - Shire - UCB Other Prominent Vendors - Amgen - Akebia Therapeutics - Boehringer Ingelheim - Celltrion - ChemoCentryx - Ferring Pharmaceuticals - Galapagos - Genentech - Merck - Mitsubishi Tanabe - Novartis - Novo Nordisk - Pfizer - Salix Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/vhn6mx/global
BIIB: 385.05 (-6.69), NVO: 58.16 (-0.38), MRK: 58.07 (-0.06), SLXP: 172.96 (+0.15), AMGN: 164.10 (-0.15), AKBA: 11.07 (+0.08), NVS: 103.05 (+1.75)
Earnings Loom For Handful Of Top Big Cap 20 Stocks
at Investor's Business Daily - Mon Jul 20, 5:50PM CDT
A handful of Big Cap 20 stocks are due to report quarterly earnings this week, but only one is expected to post accelerating profit growth. Starbucks (SBUX) will report fiscal Q3 earnings Thursday. Profit is seen rising 21% to 41 cents a share, which...
SBUX: 56.56 (-0.13), BIIB: 385.05 (-6.69), ILMN: 219.94 (+2.45), ABBV: 70.52 (-0.04), CELG: 139.01 (+0.75)
Biogen Idec Rises 1.06% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Mon Jul 20, 3:51PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $403.01 to a high of $409.40. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high of $407.83 on volume of 1.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BIIB: 385.05 (-6.69)
SmarTrend Watching for Potential Pullback in Shares of Biogen Idec After 1.06% Gain
Comtex SmarTrend(R) - Mon Jul 20, 3:51PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $403.01 to a high of $409.40. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high of $407.83 on volume of 1.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BIIB: 385.05 (-6.69)
Stocks Extend Losses; Amazon, Visa Headline After-Hours Action
at Investor's Business Daily - 1 hr 36 mins ago
Sellers were in the stock market again Thursday as Wall Street digested another avalanche of second-quarter earnings reports. At the close, the Dow Jones industrial average had lost 0.7%, the S&P 500 fell 0.6% and the Nasdaq had shed 0.5%....
BIIB: 385.05 (-6.69), UA: 95.93 (+6.56), AMZN: 482.18 (-6.09), VRX: 253.84 (+14.92), SAVE: 61.37 (+1.32), V: 71.75 (-0.22), CYBR: 61.72 (+4.22), ABBV: 70.52 (-0.04), FTNT: 46.83 (+4.53)
Eli Lilly, Biogen Present Data at Alzheimer's Association - Analyst Blog
Zacks Equity Research - Zacks Investment Research - 2 hrs 47 mins ago
Eli Lilly (LLY) and Biogen presented data on their Alzheimer's disease candidates, solanezumab and aducanumab, respectively at the Alzheimer's Association.
BIIB: 385.05 (-6.69), AGIO: 118.42 (+1.04), AMAG: 71.31 (-1.23), LLY: 86.76 (+0.38)
Should You Buy Biogen (BIIB) Ahead of Earnings? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jul 23, 7:40AM CDT
Analysts have very recently bumped up their estimates for Biogen, suggesting that a beat might be in the cards for the upcoming report
BIIB: 385.05 (-6.69)
Downgrade Alert for Biogen Idec (BIIB)
Comtex SmarTrend(R) - Thu Jul 23, 7:14AM CDT
Biogen Idec (NASDAQ:BIIB) was downgraded from Overweight to Neutral at Piper Jaffray today. The stock closed yesterday at $391.74 on volume of 4.0 million shares, above average daily volume of 1.4 million. Biogen Idec share prices have moved between a 52-week high of $480.18 and a 52-week low of $290.85 and closed yesterday at 35% above that low price at $391.74 per share. The 200-day and 50-day moving averages have moved 0.32% higher and 0.16% higher over the past week, respectively.
BIIB: 385.05 (-6.69)
Will Biogen Earnings Be a Biotech Bloodbath?
at The Street - Thu Jul 23, 6:43AM CDT
Biogen is one of the greatest biotech companies on the planet, and it reports earnings on Friday morning. It could disappoint investors again.
BIIB: 385.05 (-6.69)
Illumina Breaches Key Level On Q2 Sales Miss
at Investor's Business Daily - Wed Jul 22, 3:54PM CDT
Illumina (ILMN) surpassed second quarter earnings estimates late Tuesday but missed on revenue for the first time in six years. Analysts expected a beat-and-raise from the maker of gene sequencing systems, so its shares suffered in the stock market...
BIIB: 385.05 (-6.69), VRX: 253.84 (+14.92), DGX: 74.40 (+1.93), ILMN: 219.94 (+2.45), ABBV: 70.52 (-0.04), CELG: 139.01 (+0.75)
Isis Pharmaceuticals Begins Huntington's Disease Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 22, 2:20PM CDT
Isis Pharmaceuticals' (ISIS) Huntington's disease candidate, ISIS-HTTRx, moves into a phase I/IIa study; earns a milestone payment of $22 million from Roche.
BIIB: 385.05 (-6.69), ISIS: 55.08 (-0.30), AMAG: 71.31 (-1.23)
5 Stocks to Watch for Thursday and Friday.
ESTMZ - Wed Jul 22, 10:51AM CDT
Reports for Thursday, July 23 Report for Friday, July 24 Under Armour (UA) Under Armour (UA) will report its FQ2 ’15 results before the opening bell on Thursday. For Under Armour, while sales are expecting to continue their streak of...
SBUX: 56.56 (-0.13), AMZN: 482.18 (-6.09), BIIB: 385.05 (-6.69), UA: 95.93 (+6.56), DNKN: 53.75 (-2.78), SPY: 210.18 (-1.19), CMG: 725.94 (+0.12), MCD: 97.09 (-0.49), KKD: 18.22 (-0.29), YUM: 87.82 (-1.49)
US Blood Cancer Drug Market & Pipeline Analysis 2015
M2 - Wed Jul 22, 10:15AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hp4cd3/us_blood_cancer) has announced the addition of the "US Blood Cancer Drug Market & Pipeline Analysis 2015" report to their offering. Chemotherapeutic drugs are widely used therapeutics for the treatment of blood cancer in US. The future would witness a novel chemotherapeutics which are currently under various stages of research and development. Liposomal, pegylated and other improved versions are being made to offer higher therapeutic benefit along with minimized side effects. This will also help in increasing the number of indications and market volume by introduction of new chemotherapeutic products. They would have higher safety and efficacy levels as compared to their traditional counterparts. It will help in occupying large market shares and compete effectively with presently available drugs. Monoclonal antibodies are known for their superior pharmacological profiles and fewer side effects due to which they are widely accepted. Few monoclonal antibodies have been already introduced in US market. They have been able to generate significant revenues which are encouraging pharmaceutical companies to venture in this segment. Tyrosine kinase inhibitors are another major component of this market which has received lots of commercial success owing to their superior pharmacological efficacy. Both of them are far superior then chemotherapeutics and it is expected that blood cancer drugs belonging to different drug categories would be introduced in US market. Innovative blood cancer therapeutics is likely to generate huge revenues for the pharmaceutical companies in the next few years. However, few hurdles have to be passed like heterogeneous nature of blood cancer; it consists of different cells with different functions and it becomes difficult to eliminate them with single type of therapeutic. In this regard, only single therapeutic for different blood cancers have been introduced in US market till date. This strategy is likely to be followed by other pharmaceutical companies due to which competition in multiple blood cancer segments will increase. Market introduction of such therapeutics is likely to be widely accepted leading to generation of significant revenues. More blood cancer therapeutics is likely to enter in US market due to which its size will increase. "US Blood Cancer Drug Market & Pipeline Analysis 2015" Report Highlights: - Blood Cancer Incidence & Prevalence - Blood Cancer Drug Market Overview - Blood Cancer Drug Market Dynamics - Leukemia, Lymphoma & Myeloma Drug Clinical Pipeline Insight - Leukemia, Lymphoma & Myeloma Drug Clinical Pipeline: 435 Drugs - Majority Drugs in Phase-I Clinical Trials: 128 Drugs - Marketed Leukemia, Lymphoma & Myeloma Drug Clinical & Patent Analysis - Marketed Leukemia, Lymphoma & Myeloma Drug: 48 Drugs Key Topics Covered: 1. US Blood Cancer Incidence & Prevalence 2. US Blood Cancer Drug Market Overview 3. US Blood Cancer Drug Market Dynamics 4. US Blood Cancer Drug Market Future Prospects 5. Mechanism of Blood Cancer Therapeutics 6. Leukemia Drug Clinical Pipeline by Company & Phase 7. Marketed Leukemia Drug Clinical Insight 8. Lymphoma Drug Clinical Pipeline by Company & Phase 9. Marketed Lymphoma Drug Clinical Insight 10. Multiple Myeloma Drug Clinical Pipeline by Company & Phase 11. Marketed Multiple Myeloma Drug Clinical Insight 12. Multiple Blood Cancer Drug Clinical Pipeline by Company & Phase 13. Marketed Multiple Blood Cancer Drug Clinical Insight 14. Competitive Landscape - ARIAD Pharmaceuticals - Actelion Pharmaceuticals - Amgen - Astellas Pharma - Baxter BioScience - Bayer HealthCare Pharmaceuticals Inc. - Biogen Idec - Bristol-Myers Squibb - CASI Pharmaceuticals - Celera Genomics Group - Celgene Corporation - Eisai Co Ltd - Genmab - Gilead Sciences - GlaxoSmithKline - Hospira - Johnson & Johnson - Millennium Pharmaceuticals - Nova Laboratories - Novartis - Onxeo SA - Onyx Pharmaceuticals - Otsuka Pharmaceutical - Pfizer - Roche - SRI International - Scripps Clinic - Seattle Genetics - Southern Research Institute - Tekmira Pharmaceuticals Corporation - Teva Pharmaceutical Industries - Yakult Honsha For more information visit http://www.researchandmarkets.com/research/hp...ood_cancer
BIIB: 385.05 (-6.69), TKMR: 10.73 (+0.39), AMGN: 164.10 (-0.15), GSK: 42.00 (-0.30), BMY: 68.24 (-1.13), CASI: 1.64 (-0.07), JNJ: 100.20 (+0.02), GILD: 117.66 (+0.22), TEVA: 62.51 (unch), ARIA: 8.05 (-0.18), NVS: 103.05 (+1.75), CELGZ: 2.20 (-0.09)
Biotech Stock Roundup: Amgen PCSK9 Inhibitor First to Gain Approval, Exelixis Up on Positive Data - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Jul 22, 9:52AM CDT
Amgen's (AMGN) potential blockbuster, Repatha, is the first PCSK9 inhibitor to gain approval in the world for the treatment of high cholesterol.
BIIB: 385.05 (-6.69), ALXN: 207.84 (+1.68), AMGN: 164.10 (-0.15), ABBV: 70.52 (-0.04), REGN: 556.61 (+0.08), FPRX: 24.47 (-0.58), EXEL: 5.88 (-0.43)
Eli Lilly's Solanezumab Is the Alzheimer's Drug Equivalent of the Internet Dress
at The Street - Wed Jul 22, 6:00AM CDT
Lilly uses a new but contentious methodology to suggest treatment benefit from its experimental Alzheimer's drug.
BIIB: 385.05 (-6.69), LLY: 86.76 (+0.38)
Biogen Presents New Data from Phase 1B Study of Investigational Alzheimer's Disease Treatment Aducanumab (BIIB037) at Alzheimer's Association International Conference(R) 2015
Business Wire - Wed Jul 22, 5:45AM CDT
Today Biogen (NASDAQ: BIIB) announced new results from a prespecified interim analysis of PRIME, the Phase 1b placebo-controlled study of aducanumab (BIIB037) in patients with prodromal or mild Alzheimer's disease (AD). In this analysis, which includes patients treated up to 54 weeks with the 6 mg/kg dose, aducanumab demonstrated acceptable safety and tolerability, and the findings reinforce the previously reported results from PRIME. These data are being presented today at the Alzheimer's Association International Conference(R) 2015 (AAIC(R)) in Washington, D.C.
BIIB: 385.05 (-6.69)
Big Week for Biogen
Brian Orelli, The Motley Fool - Motley Fool - Tue Jul 21, 4:48PM CDT
Biogen 's investors are in store for a double dose of news this week. On Wednesday, the biotech is scheduled to present data for its Alzheimer's disease drug, aducanumab, and then on Friday we'll get second-quarter earnings from Biogen. Which will...
BIIB: 385.05 (-6.69)
Celgene Buys Receptos. Is Arena Pharmaceuticals Next?
Brian Orelli, The Motley Fool - Motley Fool - Tue Jul 21, 3:27PM CDT
Arena Pharmaceuticals (NASDAQ: ARNA) jumped more than 6% last Wednesday. But it had nothing to do with the biotech's only approved drug, obesity treatment Belviq. It wasn't even anything Arena Pharmaceuticals did. Instead, it appears the bump...
BIIB: 385.05 (-6.69), RCPT: 228.27 (-0.13), ARNA: 4.15 (-0.10), NVS: 103.05 (+1.75), CELG: 139.01 (+0.75)
Will AmerisourceBergen (ABC) Disappoint Earnings in Q3? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jul 21, 11:50AM CDT
AmerisourceBergen carries a Zacks Rank #4 (Sell) with an Earnings ESP of 0.00% and is scheduled to report third-quarter fiscal 2015 results on Jul 23, 2015.
BIIB: 385.05 (-6.69), ABC: 110.12 (-4.83), WBA: 95.48 (-1.16), MDCO: 34.00 (+0.16)
Why This Analyst Expects New Alzhemier’s Trials Could Produce the Most Important Drugs in History
ESTMZ - Tue Jul 21, 11:24AM CDT
Welcome to the July 21st edition of This Week on Estimize. We are pleased to be joined by Joe McCann, former biotech analyst and founder of Slingshot Insights, a company that works to provide professional caliber investment tools to sophisticated...
BIIB: 385.05 (-6.69), SPY: 210.18 (-1.19), GILD: 117.66 (+0.22), ZGNX: 20.27 (-0.71), UTHR: 175.10 (+0.50), RTRX: 34.18 (-0.75), LLY: 86.76 (+0.38), CELG: 139.01 (+0.75), XOMA: 1.04 (+0.04)
Global Inflammatory Bowel Disease Market 2015-2019 - Dominance of Market by Biologics
M2 - Tue Jul 21, 10:17AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vhn6mx/global) has announced the addition of the "Global Inflammatory Bowel Disease Market 2015-2019" report to their offering. This report covers the present scenario and the growth prospects of the Global Inflammatory Bowel Disease market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various drugs used in the treatment of inflammatory bowel disease. The market includes data from the sales of various drusg which are used for the treatment of Crohn's Disease and Ulcerative Colitis. The dominance of the market by biologics used to treat patients suffering from the disease is one of the emerging trends. Biologics are expected to become a preferred treatment option for the medical fraternity, patients, and the families of patients during the forecast period. This leads to a rise in the number of treatment-seeking patients, which increases the overall consumption of medicines. According to the report, the high prevalence of inflammatory bowel disease among the population resulting in a rise in the number of treatment-seeking patients has led to increased consumption of medications, thereby having a positive impact on the market share of the vendors. Further, the report states the high cost of drugs used to treat patients suffering from inflammatory bowel disease is one of the major challenges hindering the growth of the market. On the basis of the functioning of the drugs used for treatment, the Global Inflammatory Bowel Disease market is categorized into three segments. - 5-ASA - Antibiotics - Immunomodulators On the basis of the type of molecule used for treatment, the Global Inflammatory Bowel Disease market is categorized into two segments. - Biologics - Small Molecules On the basis of route of administration adopted for the treatment, the Global Inflammatory Bowel Disease market is categorized into two segments. - Oral - Parenteral On the basis of the form of drug used to treat the disease, the Global Inflammatory Bowel Disease market is categorized into two segments. - Solid - Liquid Key Vendors - Abbvie - Biogen Idec - Janssen Pharmaceuticals - Merck & Company - Shire - UCB Other Prominent Vendors - Amgen - Akebia Therapeutics - Boehringer Ingelheim - Celltrion - ChemoCentryx - Ferring Pharmaceuticals - Galapagos - Genentech - Merck - Mitsubishi Tanabe - Novartis - Novo Nordisk - Pfizer - Salix Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/vhn6mx/global
BIIB: 385.05 (-6.69), NVO: 58.16 (-0.38), MRK: 58.07 (-0.06), SLXP: 172.96 (+0.15), AMGN: 164.10 (-0.15), AKBA: 11.07 (+0.08), NVS: 103.05 (+1.75)
Earnings Loom For Handful Of Top Big Cap 20 Stocks
at Investor's Business Daily - Mon Jul 20, 5:50PM CDT
A handful of Big Cap 20 stocks are due to report quarterly earnings this week, but only one is expected to post accelerating profit growth. Starbucks (SBUX) will report fiscal Q3 earnings Thursday. Profit is seen rising 21% to 41 cents a share, which...
SBUX: 56.56 (-0.13), BIIB: 385.05 (-6.69), ILMN: 219.94 (+2.45), ABBV: 70.52 (-0.04), CELG: 139.01 (+0.75)
Biogen Idec Rises 1.06% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Mon Jul 20, 3:51PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $403.01 to a high of $409.40. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high of $407.83 on volume of 1.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BIIB: 385.05 (-6.69)
SmarTrend Watching for Potential Pullback in Shares of Biogen Idec After 1.06% Gain
Comtex SmarTrend(R) - Mon Jul 20, 3:51PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $403.01 to a high of $409.40. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high of $407.83 on volume of 1.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BIIB: 385.05 (-6.69)
